☰

Ziyang Yu, Ph.D.

Affiliations: 
2011 Boston University, Boston, MA, United States 
Area:
Biochemistry, Genetics, Oncology
Google:
"Ziyang Yu"
Mean distance: (not calculated yet)
 
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Gail E. Sonenshein grad student 2011 Boston University
 (Genetic and molecular analysis of the function of the tumor suppressor lysyl oxidase propeptide and its target Blimp1 in cancer.)

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Hamilton E, LoRusso P, Ma C, et al. (2020) Abstract P5-11-01 : Phase 1 dose escalation study of a novel selective androgen receptor modulator (SARM), RAD140, in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer Cancer Research. 80
He S, Conlan MG, Arlt H, et al. (2020) Abstract P5-05-01: Novel mechanisms of action of selective androgen receptor modulator RAD140 in AR+/ER+ breast cancer models Cancer Research. 80
Yu Z, He S, Miller C, et al. (2019) Abstract P4-13-02: Selective androgen receptor modulator RAD140 inhibits the growth of endocrine-resistant breast cancer models with defined genetic backgrounds Cancer Research. 79
Hamilton E, Vidula N, Ma C, et al. (2019) Abstract OT1-02-02: A phase 1, first-in-human, multi-part study of RAD140, an oral nonsteroidal selective androgen receptor modulator, in postmenopausal women with hormone receptor positive breast cancer Cancer Research. 79
Hamilton E, Vidula N, Ma C, et al. (2019) Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer (BC) Annals of Oncology. 30
Yu Z, He S, Wang D, et al. (2017) Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor Positive Breast Cancer Models with a Distinct Mechanism of Action. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Yu Z, He S, Wang D, et al. (2017) Abstract 3609: RAD140, a selective androgen receptor modulator, has a differentiated mechanism of action in AR/ER positive breast cancers Cancer Research. 77: 3609-3609
Yu Z, He S, Brown J, et al. (2017) Abstract 3608: RAD140, an orally available selective androgen receptor modulator, inhibits the growth of AR/ER positive breast cancer cell line- and patient-derived xenograft models Cancer Research. 77: 3608-3608
Gao S, Ye H, Gerrin S, et al. (2016) ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Yu Z, Brown J, Saeh J, et al. (2016) RAD140, an orally available selective androgen receptor modulator, exhibits potent anti-tumor activity in ER+AR+ breast cancer models European Journal of Cancer. 69: S149
See more...